Cardinal Health Speeds Delivery of Endovasc's Amazingly Safe New Heart Drug - To Be Used to Grow New Blood Vessels After Heart Attack.

Business/Health Writers

MONTGOMERY, Texas--(BUSINESS WIRE)--Oct 28, 2002

Endovasc Ltd. Inc. (OTCBB:ENVC) - a biotechnology company with two potential $1 billion dollar blockbuster cardiovascular drugs approved for final FDA Phase III human trials - announced today that Cardinal Health (NYSE:CAH) is one month ahead of the original schedule in its process of formulating the ANGIOGENIX(TM) drug according to cGMP FDA standards.

Cardinal Health has substantiated the validation process for two of the three doses to be formulated, previously done at the University of Kentucky, therefore eliminating the need for repeat validation. This should cut 4-5 weeks off of the completion of the project, making the ANGIOGENIX(TM) drug available sooner than originally anticipated. ANGIOGENIX(TM) is the revolutionary new treatment that has shown to recruit the body's own stem cells that help grow new blood vessels predicted to relieve chest pain and improve heart function in patients with chronic myocardial ischemia. According to Endovasc, approximately 750,000 U.S. patients could be treated for this condition every year.

Cardinal Health, Inc. - with over $51 billion in sales, and a market capitalization of almost $30 billion - is a leading provider of products and services to healthcare providers and manufacturers, helping them improve the efficiency and quality of healthcare.

Endovasc should already begin receiving the first ANGIOGENIX(TM) drugs in December. The company is currently evaluating the possibility of starting an FDA pilot trial with one of the doses immediately upon receipt of that formulated drug. This would provide an opportunity for five human patients with no other treatment options left to be treated with ANGIOGENIX(TM). The pilot study would be performed for compassionate reasons only, and even though it could provide valuable data for Endovasc, it would not be part of the final FDA Phase III human clinical trials.

Cardiovascular and metabolic markets account for more than USD $69 billion in sales volume per year -- 25% of the entire pharmaceutical market. Cardiovascular diseases are the number one cause of death in the Western world today. They also account for 50% of deaths worldwide, nearly double of those caused by cancer, the second most prevalent cause of death. It is estimated that in the United States alone, the economic cost of cardiovascular diseases is over USD $250 billion per year. Endovasc has two potential blockbuster cardiovascular drugs approved for final FDA Phase III human clinical trials.

Recent experiments suggest that the company's ANGIOGENIX(TM) treatment can stimulate the process of angiogenesis and recruit the body's own stem cells to spur the growth of new heart vessels predicted to relieve chest pain and improve heart function. The company's other late stage drug, Liprostin(TM), is a liposomal prostaglandin-based treatment that studies suggest will prevent restenosis (re-blockage of arteries), thus increasing blood circulation, preventing clotting, and reducing leg pain by increasing the oxygen and nutrients in increased blood flow.

About Endovasc

Endovasc's products include ANGIOGENIX(TM), the revolutionary new treatment that has shown to recruit the body's own stem cells that help grow new blood vessels predicted to relieve chest pain and improve heart function in patients with chronic myocardial ischemia; Liprostin(TM), a liposomal prostaglandin-based treatment that studies suggest may prevent restenosis (re-blockage of arteries), increase circulation, and reduce leg pain in patients due to poor blood flow from vascular disease. Additionally, the company has biodegradable stents, drug-delivery stents and newly discovered nutraceutical applications that may accelerate therapeutic muscle development (stroke, muscular dystrophy diseases, etc.) and quality-of-life for people seeking to increase muscle mass. Another product using prostaglandin E-1 (PGE-1) precursor will be produced as a dietary supplement for obesity and insulin control in overweight diabetic women.

Endovasc believes that its nutraceutical nicotine-base lotions for local therapeutic muscle mass enhancement, (which, according to the company, will contain nicotine levels too low to cause habituation or to produce the typical euphoria effects from smoking) combined with high protein complexes could become blockbuster nonprescription products, producing positive cash flow even sooner than its later stage drugs because they are not subject to the FDA approval process.

Endovasc Ltd., Inc., established in 1996, is a biotechnology company focused in the area of cardiovascular disease, pioneering drug delivery technology designed to deliver and release drugs to their intended targets in an efficient and controlled manner. The company's pipeline of products and processes include: Liprostin(TM), ANGIOGENIX(TM), PROStent(TM) stent-coating technology, and a biodegradable stent prosthesis.

The foregoing statements are made under the "Safe Harbor" Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements that involve risks and uncertainties that may not be evident at the time of this release. For more information about Endovasc, please visit www.endovasc.com. Investor questions and requests for materials can be submitted online at [e-mail].